SHARED BURDEN How Friends of Cancer Research Is Taking Lessons from PD-L1 to Gain Consensus for Assaying Tumor Mutation SHARED BURDEN Burden
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Corporate Governance
Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020. -
Notice of Meeting for the Eighteenth Annual General Meeting (AGM) of Glaxosmithkline Plc
GlaxoSmithKline plc Image HIV virus Notice of Annual General Meeting Thursday 3 May 2018 at 2.30pm This document is important and requires your immediate attention. If you are in any doubt as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser immediately. If you have sold or otherwise transferred all of your shares, please pass this document, together with the accompanying documents, to the purchaser or transferee, or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares. 2 29 March 2018 To the holders of the company’s Ordinary Shares and American Depositary Shares. Dear Shareholder, Annual General Meeting 2018 I am pleased to enclose the Notice of Meeting for the eighteenth Annual General Meeting (AGM) of GlaxoSmithKline plc. The AGM will be held on Thursday 3 May 2018 at 2.30pm at the QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE. If you will not be attending, you may appoint a proxy by completing and returning the enclosed proxy form. Alternatively, you may appoint a proxy electronically via www.shareview.co.uk, www.sharevote.co.uk or, if you hold your shares in CREST, via the CREST system. Notice of your appointment of a proxy should reach the company’s registrar, Equiniti, by 2.30pm on Tuesday 1 May 2018. If you hold your shares through a nominee service, please contact the nominee service provider regarding the process for appointing a proxy. Included in the business of the AGM are resolutions to receive and adopt the Directors’ Report and the Financial Statements for 2017, to approve the Annual report on remuneration for the year ended 31 December 2017 and to confirm the appointment of Deloitte LLP as the company’s auditors. -
Curriculum Vitae Professor Mark John Pallen
Curriculum Vitae Professor Mark John Pallen MA (Hons) Cantab, MBBS, MD, PhD January 2014 Mark Pallen — Curriculum vitae Personal Details Name Mark John Pallen Date of Birth 6 July 1960 Nationality British Address 17 Lodge Drive, Malvern Worcestershire, WR14 4LS E-mail address [email protected] Telephone 01684 567710 (home); 07824 086946 (mobile) Web Page: http://tinyurl.com/ncul2p3 Twitter: http://twitter.com/mjpallen YouTube Channel: http://www.youtube.com/user/pallenm/ Education and Qualifications PhD 1998 Imperial College, London An investigation into the links between stationary phase and virulence in Salmonella enterica enterica serovar Typhimurium MD 1993 St Bartholomew's Hospital Medical College Detection and characterisation of diphtheria toxin genes and insertion sequences MRCPath by examination in Medical Microbiology 1991 (upgraded to FRCPath 2005) MB BS 1981-84 London Hospital Medical College Undergraduate Prizes: LEPRA National Essay Prize, 1982 Turnbull Prize in Pathology, 1983, 1984 Sutton Prize in Pathology, 1983 BA (Hons) in Medical Sciences 1978-81 University of Cambridge Fitzwilliam College (Lower Second, converted to MA, 1985) Page 1 Mark Pallen — Curriculum vitae Employment Professor of Microbial Genomics Head of Division of Microbiology and Infection Apr 2013-now Warwick Medical School, University of Warwick Professor of Microbial Genomics 2001-2013 University of Birmingham Professor and Head of Department 1999-2001 Department of Microbiology and Immunobiology Queen’s University, Belfast Senior Lecturer (Honorary Consultant) 1992–99 Department of Medical Microbiology St Bartholomew's and the Royal London School of Medicine and Dentistry (Queen Mary Westfield College) Visiting Research Fellow 1994–97 Department of Biochemistry Imperial College of Science, Technology and Medicine (on a Wellcome Trust Research Leave Fellowship, working at Imperial, while still employed by Barts) Lecturer (Hon. -
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION to BE INCLUDED in STATEMENTS FI
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 84833T 10 3 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 6, 2017 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. -
Faculty in Pharmacotherapy
College Of Pharmacy Faculty Research Publication Revised January 2017 1 Table of Contents Faculty in Medicinal Chemistry . .03 Kuberan Balagurunathan………………………………………………………………………….………… 04 Amy M. Barrios………………………………………………………………………………………………………. 05 Grzegorz Bulaj………………………………………………………………………………………………….…. 06 Tom Cheatham III……………………………………………………………………………………………………. 07 Darrell Davis………………………………………………………………………………………………………... 08 Raphael Franzini…………………………………………………………………………………………………... 09 Margo Haygood……………………………………………………………………………………………………... 10 Chris Ireland………………………………………………………………………………………………….……... 11 Zhenjian Lin…………………………………………………………………………………………………………... 12 Shuanghu Liu…………………………………………………………………………………………………………. 13 Siam Oottamasathien..…………………………………………………………………………………………... 14 Glen Prestwich…….………………………………………………………………………………………….…… 15 Eric Schmidt….…………………………………………………………………………………………….………... 16 Robert Selliah………………………………………………………………………………………………………. 17 Jaclyn Winter………………………………………………………………………………………………………...18 Faculty in Pharmaceutics & Pharmaceutical Chemistry . .19 You Han Bae…………………………………………………………………………………………………………… 20 Mingnan chen….………………………………………………………………………………………………….…. 21 Andrew Dixon………………………………………………………………………………………………………... 22 Shuyun Dong…………………………………………………………………………………………………………. 23 Hamid Ghandehari…..……………………………………………………………………………………….……. 24 David W. Grainger……………………………………………………………………………………………….… 25 James Herron………………………………………………………………………………………………………… 26 Sung Wan Kim………………………………………………………………………………………………………… 27 Jindrich Henry Kopecek…………………………………………………………………………………….…. -
And Ph-Responsive Hydrogels and Their Controlled Release Properties
Therrno- and pH-Responsive Hydrogels and Their Controlled Release Properties Hua Yu B.S., China Textile University, China, 1984 M.S., China Textile University, China, 1987 A dissertation submitted to the faculty of the Oregon Graduate Institute of Sciences & Technology in partial fulfillment of the requirements for the degree Doctor of Philosophy in Chemistry Feburary, 1994 The dissertation "Thermo- and pH-Responsive Hydrogels and Their Controlled Release Properties" by Hua Yu has been examined and approved by the following Examination Committee: --DavidAssociatew. ProfessorGrainger:T~sis Adfisor Nini~Blackburn Professor HanS. Hoffman Professor, University of W ciences University To My Parents Acknowledgments I would like to thank my dissertation committee, Dr. David Grainger, Dr. Ninian Blackburn, Dr. Allan Hoffman, Dr. Jeffrey Hollinger, for reviewing my dissertation, special thanks to Dr. David Grainger, my thesis advisor. This research was made possible through funding from Merck Academic Predoctoral Fellowship. Discussions with Dr. Allan Hoffman, Dr. Teruo Okano, Dr. You Han Bae, and Dr. Sung-Wan Kim are gratefully appreciated. The help provided in the laboratory by Dr. Joan Sanders-Loher, Dr. Tom Loher, Dr. Jim Huntzicker and the help provided on the document by Nancy Christie, Terry Hadfield are gratefully appreciated. Also, I would like to give thanks to Jennifer Peterson and Tracey Fuller for spending their summer internship with me. TABLE OF CONTENTS Dedication i .. Acknowledgments 11 Nomenclature vii List of Figures viii List -
To Download a PDF of an Interview with Dr
INTERVIEW VIEW Interview A Transformative INTER Time for Cancer Research An Interview with Dr. Laurie H. Glimcher, President and Chief Executive Offi cer, Dana-Farber Cancer Institute Over the past fi ve years, Dana-Farber has fi gure out how we can make 100 percent of had its fi ngerprints on half of the new cancer patients who have those particular tumors drugs. respond to immunotherapy. There are also When you look at the advances taking many tumors that don’t respond to immuno- place at Dana-Farber, should there be more therapy, so we have to fi gure out how to har- optimism that we’re going to achieve the ness the immune system in those patients so Laurie H. Glimcher results needed to cure cancer? that, someday, 100 percent of all patients will It’s an incredible and transformative time respond to immunotherapy. EDITORS’ NOTE Immediately prior to assum- for cancer research. The history of innovation It will take basic and translational research ing her current post, Dr. Laurie Glimcher at Dana-Farber is well-known. Sidney Farber at many different institutions, both in academia served as the Stephen and Suzanne Weiss was the fi rst person to use chemotherapy to and in the private sector, to fi gure things out. I’m Dean and Professor of Medicine at Weill cure acute leukemia, so we have a long history optimistic about success and eventually making Cornell Medical College in New York City, and of innovation. cancer a chronic disease. I hesitate to use the Provost for Medical Affairs at Cornell University. -
Going with the Flow the Money Flow Issue
Drugs&DealersMagazine FEATURE: MedCity comes online Dr Eliot Forster, CEO of Creabilis and Chair of MedCity talks A Biotech and Money Publication Issue 1 | June 2014 collaboration, innovation and a new era for UK bioscience Removing the hype from IPO Building the next billion dollar businesses Horizon Discoverys’ CEO, Dr Darrin Disley talks education, Nigel Pitchford, Imperial Innovations’ CIO talks Circassia, public their high profile IPO and future growth market momentum and its own unique investment approach Tapping the markets Minding (and funding) the gap Dr Chris Blackwell, CEO of Vectura and Peter Grant, CEO of David Grainger of Index Ventures discusses their ‘market Skyepharma discuss their recent successful placements backwards’ approach to spotting innovation Taking aim at the Alternative Investment Market The Elephant in the room Lucy Tarleton of London Stock Exchange discusses IPO cycles, successful Sam Fazeli of Bloomberg and Dr Paul Cuddon of Peel Hunt floats and their new Elite programme talk market trends and dispelling the ‘B’ word Going with the Flow The money flow issue. Biotech and Money Ltd. The Euston Office | One Euston Square | 40 Melton St. | London | NW1 2FD Tel: +44 (0) 203 5744619 | Email: [email protected] Welcome A little more about Biotech and Money Biotech and Money is the first truly crowd sourced member’s only community of senior level executives from the global biopharma industry. Terence O’Dwyer The global community provides an exclusive nexus between bioscience, investors, financiers, legal and professional advisors. It’s provides a new approach to matching innovation with investors and partners. Our community helps catalyse early stage innovation through peer-to-peer education and Neil Darkes knowledge sharing, networking, partnering and Dear Reader, deal making to champion the most exciting and innovative ideas. -
Oversight Committee Board Packet
Oversight Committee Meeting February 21, 2018 Summary Overview of the February 21, 2018, Oversight Committee Meeting This summary provides an overview of major agenda items and background on key issues for Committee consideration at the February 21, 2018, Oversight Committee meeting. CEO Report Wayne Roberts will present the CEO’s report and address issues including new personnel, available grant funds, and other topics. Mr. Roberts will also present his annual report required by Tex. Health & Safety Code § 102.260(c). Grantee Presentation – Asuragen, Inc. Dr. Gary Latham will report on Asuargen’s activities and achievements. Asuragen received a $6.8 million Commercialization/Product Development grant in 2012. Chief Compliance Officer Report Vince Burgess will report on the status of required grantee reports, financial status report reviews, desk reviews and site visits, annual compliance attestation, single audit tracking, and training. Chief Scientific Officer Report and Grant Award Recommendations Dr. James Willson will provide an update on the Academic Research Program and present the Program Integration Committee’s (PIC) award recommendations for Academic Research grant awards. CPRIT does not publicly disclose information related to the Academic Research grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. Chief Prevention and Communications Officer Report and Grant Award Recommendations Dr. Becky Garcia will report to the Oversight Committee on the Prevention Program activities and present the PIC’s award recommendations for Prevention grant awards. She will also present the agency’s communications update, including a review of CPRIT’s 2017 Innovations Conference. -
Fondo De Innovación Academica Programa Mecesup 2
TERCER CONCURSO DE PROYECTOS FONDO DE INNOVACIÓN ACADEMICA PROGRAMA MECESUP 2 FORMULARIO UNICO DE PRESENTACIÓN DE PROYECTOS 2008 - UNIVERSIDADES - PARA LOS SIGUIENTES EJES Y TEMAS: EJE I DESARROLLO DE PERSONAL ACADEMICO Y PARA LA GESTIÓN. Tema 1 Personal Académico para la Investigación y el Postgrado. Tema 2 Capacidades de Gestión Académica. Tema 3 Capacitación Docente. EJE II DESARROLLO DE PROGRAMAS DE POSTGRADO NACIONALES. Tema 1 Consolidación de Programas de Doctorado Nacionales. Tema 2 Equipamiento Científico Mayor. Tema 3 Doctorados Nacionales Existentes. Tema 4 Evaluación de Impacto Género y Minorías. Tema 5 Nuevos Programas de Doctorado. Tema 6 Programas de Magíster en Gestión de Información y Gestión Tecnológica de Innovación. EJE III MEJORAMIENTO DE LOS RESULTADOS DOCENTES. Tema 1 Planes de Ajuste de Calidad en el Marco de la Acreditación de Programas de Pedagogía. Tema 2 Ideas Innovativas para un Mejor Aprendizaje. Tema 3 Evaluación de Impacto en el Aprendizaje. Eje IV MODERNIZACIÓN CURRICULAR BASADA EN RESULTADOS DE APRENDIZAJE Y COMPETENCIAS. Tema 1 Renovación Curricular del Pregrado. Tema 2 Diseño de Nuevas Iniciativas Curriculares. Tema 3 Implementación de Planes de Nivelación de Competencias Básicas para Estudiantes. TÍTULO PROYECTO (Defina un título breve que describa el sentido del proyecto y que incluya palabras claves que faciliten su búsqueda electrónica). Programa de Doctorado en Ciencias Médicas: Asegurando la formación de investigadores clínicos de excelencia. INSTITUCIÓN COORDINADORA (Señale la universidad que servirá de entidad coordinadora del proyecto y de interlocutora ante el Fondo de Innovación Académica, FIAC). Universidad de Chile INSTITUCION(ES) ASOCIADA (S) (Si el proyecto es asociado o en red, identifique a la(s) otra(s) universidad(es) participante(es)). -
Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30Pm
Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30pm Notice of Availability Electronic AGM The 2020 Annual Report and 2021 Notice of Annual General Meeting are now The AGM will be broadcast live for you to join and participate available to view and/or download in the Investors section of www.gsk.com electronically via the AGM website at https://web.lumiagm.com. Please refer to the enclosed AGM Guide or follow the instructions in the Notice of Meeting. You will need the following details to access the AGM website: Meeting ID: 140-105-232 SRN: PIN: Please note that due to COVID-19 restrictions, shareholders will unfortunately not be permitted to physically attend the meeting this year. How to vote your shares at the AGM Before completing the Proxy Form, please read the notes on appointing a proxy overleaf. You can submit your proxy instructions online (Option 1 below) or by completing and returning the Proxy Form to Equiniti (Option 2 below). In either case, your proxy instructions must be received by Equiniti by 2.30pm on Friday 30 April 2021. If you do not wish anyone other than the company or Equiniti to see the Proxy Form you may send it in an envelope to: FREEPOST RTHJ-CLLL-KBKU, Equiniti, Aspect House, Spencer Road, Lancing, BN99 8LU. No postage is required if posted within the United Kingdom. If the Proxy Form is posted outside of the United Kingdom, you should return it in an envelope, with the postage paid, to Equiniti, Aspect House, Spencer Road, Lancing, BN99 6DA. -
5 , 2011 Puerto Varas
CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNUAL MEETING November, 1st – 5th, 2011 Puerto Varas SPONSORS CENTER FOR AGING AND REGENERATION (CARE) CENTRO DE ESTUDIOS MOLECULARES DE LA CELULA (CEMC) CENTRO FONDAP DE REGULACION DEL GENOMA FUNDACION CIENCIA PARA LA VIDA INSTITUTE FOR CELL DYNAMICS AND BIOTECHNOLOGY (ICDB) FUNDACION CHILENA PARA BIOLOGIA CELULAR MILLENNIUM INSTITUTE FOR FUNDAMENTAL AND APPLIED BIOLOGY (MIFAB) MILLENNIUM NUCLEUS ON IMMUNOLOGY AND IMMUNOTHERAPY (MNII) MILLENNIUM NUCLEUS IN REGENERATIVE BIOLOGY (MINREB) EXHIBITORS A. BRIL Y CIA LTDA – ALATHEIA MEDICA SA - ANDES IMPORT LTDA ARQUIMED SA – BD BIOSCIENCES – BIOSCHILE IG SA – CIENTEC SA – FERMELO SA GALENICA SA – GENESYS LTDA – GENEXPRESS – LABTEC SA LONCOTEC SA – MERCK QUIMICA DE CHILE – PERKIN ELMER CHILE ROCHE CHILE – TECNIGEN SA – TCL LTDA Chilean Society for Cell Biology – XXV Annual Meeting – November 1-5, 2011 1 INDEX CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNAUAL MEETING Program…………………………………………………………………………………………………2 Plenary Lectures…………………………………………………………………………………….....40 Symposiums……………………………………………………………………………………………44 Oral Presentations……………………………………………………………………………………..54 Poster Presentations I…………………………………………………………………………………73 Poster Presentations II……………………………………………………………………………….105 Poster Presentations III……………………………………………………………………………...137 Chilean Society for Cell Biology – XXV Annual Meeting – November 1-5, 2011 2 CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNUAL MEETING NOVEMBER, 1st-5th, 2011 PUERTO VARAS P R O G R A M Chilean Society for Cell Biology – XXV Annual